Advertisement
Australia markets open in 1 hour 48 minutes
  • ALL ORDS

    8,009.40
    -40.80 (-0.51%)
     
  • AUD/USD

    0.6445
    -0.0022 (-0.35%)
     
  • ASX 200

    7,752.50
    -35.60 (-0.46%)
     
  • OIL

    85.63
    +0.22 (+0.26%)
     
  • GOLD

    2,399.20
    +16.20 (+0.68%)
     
  • Bitcoin AUD

    97,952.05
    -3,060.52 (-3.03%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

BridgeBio Pharma Full Year 2023 Earnings: Misses Expectations

BridgeBio Pharma (NASDAQ:BBIO) Full Year 2023 Results

Key Financial Results

  • Net loss: US$643.2m (loss widened by 34% from FY 2022).

  • US$3.95 loss per share (further deteriorated from US$3.26 loss in FY 2022).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

BridgeBio Pharma Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 2.1%.

Looking ahead, revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US.

ADVERTISEMENT

Performance of the American Biotechs industry.

The company's shares are down 8.6% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with BridgeBio Pharma (at least 2 which are significant), and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.